Noventra Pharma Tirzepatide (30mg Prefilled Pen)

Tirzepatide is a dual incretin receptor agonist supplied in a pre-reconstituted pen format for controlled dispensing. It is investigated for its role in metabolic and endocrine signalling pathways through activity at glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.

Tirzepatide has been studied in clinical and experimental contexts for its interaction with pathways involved in glucose regulation, insulin signalling, and energy balance.

Key Features:

• 30mg tirzepatide per prefilled pen

• Dual incretin receptor agonist: GIP and GLP-1 activity

• Prefilled pen format for controlled and consistent application

• Investigated for roles in metabolic and endocrine signalling pathways

• Studied in relation to glucose regulation and insulin-related processes

• Associated in research with energy balance and metabolic pathway activity

Suggested Use:
For use under the guidance of a qualified professional. Protocols vary depending on application and individual requirements.

Storage:

• Store at 2–8°C at all times (refrigerated)

• Do not freeze

• Protect from light

• Avoid repeated temperature fluctuations

• Use within a limited timeframe once in use (based on formulation stability)

Important Information:
Tirzepatide has been studied in clinical settings for specific indications; however, this product should be used within appropriate professional and regulatory frameworks. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Ensure compliance with applicable regulations prior to use.